Boehringer Ingelheim Articles

Eli Lilly and BI alter Yentreve/AriClaim deal

20 February 2006

NeuroSearch takes back Tesofensine after Boeh Ing abandons it

30 January 2006

Bayer Healthcare to market telmisartan in Europe

9 January 2006

Pharma price "scam has cost Missouri $19M+"

9 January 2006

Bayer said to be eyeing BI's OTC ops

19 September 2005

BI's Micardis shows good metabolic profile

12 September 2005

Ark's first-half 2005 revenue reaches L1.3 M

12 September 2005

AHF slams "record-high" price rise for BI's Aptivus

5 September 2005

WHO, US FDA to share generic HIV/AIDS Rx data

22 August 2005

South Africa's largest generics firm, Aspen, views the market

22 August 2005

ARV price cuts agreed for Latin America

15 August 2005

NZ Pharmac gets budget boost, OKs new Rx uses

8 August 2005

Aptanomics to validate targets for Boeh Ingelheim

8 August 2005

New drugs boost BI's 1st-half sales 22%

8 August 2005

Positive CHMP opinion for BI

8 August 2005

Schering-Plough recryutes John O'Mullane as VP, R&D, consumer health care

1 August 2005

US prices for new HIV/AIDS drugs are "unreasonable, unacceptable, unjustified"

1 August 2005

New French drug ban targets antibiotics

1 August 2005

BI and Genentech terminate TNKase/Metalyse trial

18 July 2005

Mayo Clinic study finds "striking" link between Parkinson's drugs and gambling

18 July 2005

Genentech posts 39% sales rise for 2nd-qtr 2005: Rituxan and Avastin are top-earners

18 July 2005

Advent of generic gabapentin impacts neuropathic pain market

18 July 2005

UPDATE: Pfizer withdraws support for Altana's lung drug Daxas on mediocre trial results

11 July 2005

US FDA "tentative OK" for Aurobindo stavudine

11 July 2005

BI's pramipexole shows promise as RLS therapy

4 July 2005

Boeh Ingelheim's Aptivus for HIV gets accelerated approval by FDA

4 July 2005

BI enters R&D accord with Avantium

4 July 2005

Boeh Ingelheim debuts new tamsulosin pill

27 June 2005

US FDA acts against Indian generics firms, and African states reject its approvals

27 June 2005

BI and Medarex enter antibody deal

20 June 2005

FDA committee OKs BI's tipranavir for HIV

6 June 2005

GSK to bid for Boots Healthcare

30 May 2005

BI/Pfizer's Spiriva improves quality of life in COPD

30 May 2005

South African pharma market $1.69B in 2005

30 May 2005

Boeh Ingel: strong data for MicardisPlus

30 May 2005

Pfizer's Celebrex gains from Bextra withdrawal

30 May 2005

ECoJ decision on Swiss/Liechtenstein SPC dates will cost pharma, say experts

16 May 2005

Daiichi FY2005 net income soars 39%

16 May 2005

MorphoSys revenues leap 72% in 1st qtr

9 May 2005

ImmunoGen, Genentech extend collaboration

9 May 2005

CORRECTION: Boehringer Ingelheim story April 11

18 April 2005

SS Pharma appoints Seiichiro Hatori as president

18 April 2005

Boeh Ingelheim posts good results for COPD inhaler

18 April 2005

BI/Eli Lilly's Yentreve effective in SUI

18 April 2005

Boehringer Ingelheim reports strong sales and income growth for 2004

18 April 2005

Another nail in the COX-2 coffin, as FDA tells Pfizer to pull Bextra from market

18 April 2005

New Zealand opposition slams Pharmac over sole supply, urges national Rx policy

18 April 2005

BI's in-house strategy still paying off, with strong sales from established drugs

11 April 2005

Boehringer Ingelheim 2004 sales up 10.5%

11 April 2005

BI and MorphoSys expand research deal

28 March 2005

Greek pharma losing private market share

21 March 2005

Greek pharma losing private market share

21 March 2005

Encouraging data for BI's RLS drug

14 March 2005

Evotec acquires rest of ENS and secures 47M euros to develop CNS pipeline

14 March 2005

South Africa awards ARV drug tenders

14 March 2005

More US FDA HIV/AIDS drug approvals "soon"

14 March 2005

Tipranavir more effective than lopinavir in HIV, study finds

7 March 2005

Positive data for Roche/Trimeris' Fuzeon in HIV suppression

7 March 2005

Boehringer Ingelheim sees strong results for tipranavir

7 March 2005

Boehringer Ingelheim and NascaCell enter alliance

21 February 2005

Astex achieves first Boeh Ing milestone

21 February 2005

ImmunoGen gives updates on BI accord

14 February 2005

Japan's Daiichi raises full-year forecast despite dip in nine-month net

14 February 2005

BioImage licenses Redistribution to Boeh Ingelheim

14 February 2005

Hitch for Pennsylvania drug pricing suit

14 February 2005

Neurosearch gets $5 million payment from Boeh Ingelheim for NS2330 development

31 January 2005

US FDA OKs first ARV triple therapy for LDCs

31 January 2005

US CDC ARV use guide update cautions over BI's Viramune, B-MS' Sustiva

31 January 2005

Japan stock market week to January 17

24 January 2005

EC OKs Cymbalta for major depression

10 January 2005

German pharma battles opinion as prices rise

10 January 2005

S African political row over BI ARV claims

10 January 2005

Eli Lilly stands out with strong new product flow; reaffirms 2004 guidance

20 December 2004

Improving the treatment of depression: duloxetine leads a new breed of therapy

22 November 2004

GSK/Boeh Ingelheim's Micardis protects against progression of diabetic nephropathy

8 November 2004

Boeh Ingelheim files NDA for tipranavir

1 November 2004

Is biotech approaching a golden era? Firms showcase technologies at BioPartnering Euro

25 October 2004

BI regains pramipexole product portfolio

25 October 2004

BI AIDS drug deal for Kenya's Cosmos

11 October 2004

Increasing HIV survival rates present new treatment challenges; Datamonitor report

4 October 2004

Boeh Ingelheim/Lilly's Yentreve has a quick onset of action in treating SUI; new study

4 October 2004

Boehringer Ingelheim buys STEAG microParts

20 September 2004

BI/Lilly's Yentreve available in Europe

20 September 2004

Evotec in deal with BI for GPCR modulator-based new medicines

20 September 2004

Pfizer and BI's Spiriva reduces COPD exacerbations significantly

13 September 2004

Winners of BI's ERS COPD research awards

13 September 2004

BioXell names Anke Domdey preclinical development director

6 September 2004

GSK: voluntary license for ARVs in South Africa

6 September 2004

Letter from the Editor

6 September 2004

Boeh Ingelheim pledges $250,000 to UCONN School of Pharmacy

23 August 2004

BI 1st-half sales up 7%

23 August 2004

MorphoSys and BI begin new Ab program

23 August 2004

BI/Lilly's Yentreve cleared for SUI in EU

23 August 2004

Boehringer Ingelheim's Mobic cleared for RA

16 August 2004

Lilly's Cymbalta OKed for depression by FDA

9 August 2004

Tokyo pharma stocks - week to August 2

9 August 2004

Boeh Ingelheim cuts back in Germany

9 August 2004

Chiron names Ursula Bartels VP and general counsel

2 August 2004

South Africa: no policy change on nevirapine

26 July 2004

South Africa ends nevirapine monotherapy in HIV PMTCT, due to resistance issues

19 July 2004

Showing 401-500 of 1098 articles

Go to beginningPreviousNextGo to end